Conduction System Pacing Versus Conventional Right Ventricular Pacing in Adults With Atrioventricular Block
Randomized Prospective Comparison of Conduction System Pacing Versus Conventional Right Ventricular Pacing in Patients With an Indication for Permanent Pacemaker Implantation
This study compares two ways of pacing the heart in adults with atrioventricular block, a condition in which electrical signals do not pass normally from the upper to the lower heart chambers. Participants must need a permanent pacemaker and have a left ventricular ejection fraction of at least 50% before implantation. Ejection fraction measures how much blood the main pumping chamber ejects with each beat.
The study will include 150 participants at Sheba Medical Center. By chance, 50 participants will receive conduction system pacing, which aims to stimulate the heart through its natural electrical conduction system, and 100 will receive conventional right ventricular pacing. Participants and treating clinicians will know which treatment is used.
The main question is whether the two pacing strategies differ in heart pumping function 24 months after implantation, taking the starting measurement into account. Researchers will also compare quality of life, heart-related emergency visits and hospitalizations, complications, pacemaker and lead function, repeat procedures, and use of healthcare resources.
Heart pumping function will be measured before implantation and at 12 and 24 months. Participants will complete the AQUAREL quality-of-life questionnaire before implantation and at 12, 24, 36, 48, and 60 months. Device follow-up will include routine clinical care and remote monitoring.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Outcomes Over Devices is a prospective, randomized, open-label, two-arm, single-center study comparing conduction system pacing (CSP) with conventional right ventricular pacing (RVP). The clinical indication for permanent pacing is established before recruitment. Randomization is 1:2 (50 CSP; 100 RVP), using a concealed computer-generated sequence with variable block sizes, stratified by baseline left ventricular ejection fraction (LVEF) of 50-59% versus at least 60%, without fixed quotas per stratum.
The primary analysis follows the intention-to-treat principle. The primary estimand is the between-arm difference in LVEF at 24 months, adjusted for baseline LVEF and stratification factors as appropriate. Post-baseline measurements at 12 and 24 months will be analyzed using a repeated-measures model with treatment arm, time, and their interaction. The 12-month evaluation is exploratory. The three AQUAREL domains will be scored and analyzed separately, with baseline adjustment and multiplicity addressed for the secondary 24-month comparisons. Detailed modeling and sensitivity analyses will be prespecified in the statistical analysis plan before unblinded comparative analyses.
Failure to achieve the allocated pacing strategy will not itself exclude a participant. Alternative pacing may be used when clinically necessary, with reasons and actual treatment documented; original allocation remains the basis for intention-to-treat analysis where possible. Actual ventricular pacing burden will be recorded and evaluated in prespecified secondary analyses. An independent Clinical Events Adjudication Committee will review prespecified clinical and device-related events, with arm masking where feasible.
The study is initiated by Sheba Medical Center. Medtronic does not fund the study; CSP systems are purchased under a discounted commercial arrangement. A separate, potentially outcome-based commercial reconciliation after 12 months does not determine clinical treatment or alter randomization, follow-up, data collection, analysis, or publication independence.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Yair Edden, MD
- Numéro de téléphone: +972-52-6667410
- E-mail: Yair.Edden@sheba.health.gov.il
Lieux d'étude
-
-
-
Tel HaShomer, Israël
- Sheba Medical Center
-
Chercheur principal:
- Yair Edden, MD
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18 years or older.
- Clinical indication for permanent pacemaker implantation due to atrioventricular block.
- Pre-implantation echocardiographic left ventricular ejection fraction of at least 50%.
- Ability to understand the study and sign informed consent.
Exclusion Criteria:
- Unable to provide informed consent.
- Estimated life expectancy of less than 12 months.
- Severe medical condition likely to prevent completion of follow-up.
- Existing indication for cardiac resynchronization therapy at recruitment.
- Required pacing system or treatment incompatible with either study arm.
- Concurrent interventional study likely to materially affect study outcomes.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Conduction System Pacing
50 participants allocated to conduction system pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead placed at the His bundle or left bundle branch area. Final lead position and programming are determined by the implanting electrophysiologist according to anatomy, electrical measurements, and clinical judgment. |
Permanent pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead targeting His-bundle or left bundle branch area pacing. Final lead placement, fixation, and programming follow electrophysiological measurements and clinical judgment. Where feasible, the same pacemaker generator platform is used in both study arms. |
|
Comparateur actif: Conventional Right Ventricular Pacing
100 participants allocated to conventional right ventricular pacing using a standard pacing lead and conventional right ventricular lead position, according to usual clinical practice at the study center. Other medical treatment and device programming are determined by clinical need. |
Permanent pacemaker implantation with a conventional right ventricular pacing lead placed at a standard right ventricular site according to usual clinical practice at Sheba Medical Center. Device programming and accompanying medical treatment are determined by clinical need. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Left Ventricular Ejection Fraction at 24 Months
Délai: 24 months after pacemaker implantation.
|
Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 24 months after implantation. The primary comparison is the between-arm difference adjusted for baseline LVEF and stratification factors as appropriate. The primary analysis follows the intention-to-treat principle. |
24 months after pacemaker implantation.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in AQUAREL Chest Discomfort Domain Score
Délai: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
Change from baseline in the AQUAREL chest discomfort domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected. |
Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
|
Change From Baseline in AQUAREL Arrhythmia Domain Score
Délai: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
Change from baseline in the AQUAREL arrhythmia domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected. |
Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
|
Change From Baseline in AQUAREL Exertional Dyspnea Domain Score
Délai: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
Change from baseline in the AQUAREL exertional dyspnea domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected. |
Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
|
Ventricular Pacing Burden
Délai: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
Percentage of ventricular beats paced, obtained from device interrogation. Actual pacing burden is an explanatory secondary variable and is not a randomization criterion. |
Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
|
Ventricular Pacing Capture Threshold
Délai: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
Ventricular capture threshold, expressed in volts, measured during device interrogation. Measurements are recorded with the corresponding device settings to assess pacing performance over follow-up. |
Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
|
Ventricular Sensing Amplitude
Délai: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
Amplitude of sensed ventricular signals, expressed in millivolts, measured during device interrogation to assess lead and device performance over follow-up. |
Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
|
Cardiac or Pacing/Procedure-Related Emergency Department Visits
Délai: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of emergency department visits related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Cardiac or Pacing/Procedure-Related Hospitalizations
Délai: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of hospital admissions related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Heart Failure Events
Délai: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of heart failure events during follow-up, reviewed by the Clinical Events Adjudication Committee. Written event definitions and adjudication procedures will be established before enrollment as specified in the protocol. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Additional Cardiac Interventions
Délai: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of additional cardiac interventions during follow-up. The indication, date, effects on LVEF or the pacing system, lead changes, and subsequent management will be recorded. Medically necessary interventions are permitted in either study arm. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Device-, Lead-, and Procedure-Related Complications
Délai: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of device-, lead-, and procedure-related complications. Events include implantation complications and lead or device problems such as infection, bleeding, pneumothorax, perforation or tamponade, lead dislodgement or fracture, insulation failure, and failure to capture or sense. Major events and relatedness will be reviewed by the Clinical Events Adjudication Committee. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Repeat Pacing Procedures, Lead Revisions or Replacements, and System Upgrades
Délai: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of repeat procedures involving the pacing system, including lead revision or replacement and system upgrade. Procedure type, indication, date, and resulting changes to the pacing system will be documented. Events will be reviewed by the Clinical Events Adjudication Committee. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Immediate Implantation Success
Délai: During the index implantation procedure
|
Successful implantation of the allocated pacing strategy, reported as the number and percentage of participants meeting the arm-specific technical success criteria. For CSP, assessment includes electrophysiological evidence of conduction-system capture, sensing, capture threshold, and impedance; RVP criteria are specified separately. Numerical thresholds and mandatory tests will be prospectively approved in the electrophysiology operational appendix before first enrollment. |
During the index implantation procedure
|
|
Pacing-System Function
Délai: From implantation through 24 months
|
Device or lead failures identified during clinical follow-up, device interrogation, or remote monitoring, including failure to capture or sense. Failures and subsequent management will be documented and relevant events reviewed by the Clinical Events Adjudication Committee. |
From implantation through 24 months
|
|
Implantation Procedure Duration
Délai: During the index pacemaker implantation procedure.
|
Duration of the index pacemaker implantation procedure, measured in minutes, compared between pacing strategies. |
During the index pacemaker implantation procedure.
|
|
Length of Hospital Stay
Délai: Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).
|
Duration of the hospital stay associated with the index pacemaker implantation, measured in days. |
Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).
|
|
Healthcare Resource Use
Délai: Day 1 (pacemaker implantation) through 24 months after implantation.
|
Healthcare resources used for implantation and follow-up, including staff time, equipment, diagnostic tests, and clinical visits. Resource categories will be recorded separately rather than combined into an unvalidated score. Detailed resource definitions and analysis procedures will be finalized in the operational procedures and statistical analysis plan. |
Day 1 (pacemaker implantation) through 24 months after implantation.
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Left Ventricular Ejection Fraction at 12 Months
Délai: 12 months after implantation
|
Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 12 months after implantation. The 12-month comparison is exploratory; the prespecified primary comparison is at 24 months. |
12 months after implantation
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chercheur principal: Yair Edden, MD, Sheba Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CTIL-YE-3634-26-SHEBA
- 3634-26-SMC (Autre identifiant: Sheba Medical Center)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .